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Renal cell carcinoma (RCC) has a potential to metastasize to almost any site and this may
occur many years following nephrectomy. We present six cases with uncommon sites
of metastasis: four patients presented with distal pancreatic metastasis and two with
duodenal/head of the pancreas metastasis. Time to metastatic disease varied from 1 to
19 years following renal surgery. For patients are alive and two succumbed to their disease.
Long-term survival can be achieved with aggressive surgical excision of disease.
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INTRODUCTION
Renal cell carcinoma (RCC) is the third most frequent malig-
nancy of the genitourinary tract and it accounts for 3% of all
adult malignancies (1). It has the highest mortality rate of the
genitourinary cancers and its incidence has been rising steadily
by 2–4% each year. If detected early, RCC is curable by excision
although a minority is at risk of recurrence (2). RCC has a poten-
tial to metastasize to almost any site (3, 4) of which duodenum and
pancreas are some of the rare locations for metastasis. Although
the majority of metastases occur within 3 years of nephrectomy, it
is a well-known fact that it can occur many years after nephrec-
tomy. Most cases of duodenal metastasis from RCC present with
upper gastrointestinal (GI) bleeding or obstructive symptoms (5).
While pancreatic involvement is usually asymptomatic and usually
detected on follow-up imaging for metastatic RCC, it may require
the aid of esophagogastroduodenoscopy (EGD) to establish the
diagnosis (6–8). Several therapeutic approaches have been docu-
mented including surgical and interventional therapy depending
on the individual cases (5, 6, 9).
In recent years, with the advent of target therapies, the progno-
sis of patients with metastatic RCC has improved (10). However,
in the absence of dramatic results, surgical excisions of isolated
metastasis continue to play a role in the treatment of metastatic
RCC (11–14).
MATERIALS AND METHODS
Within the last 10 years, six patients who were amenable to surgi-
cal excision presented to our service with metastatic disease to the
duodenal/pancreatic area (Table 1).
This is a retrospective summary of the last 10 years where we
treated six patients with duodenal/pancreatic metastasis following
surgery for RCC. The demographics of these patients are presented
on Table 1.
There were two males and four female patients varying in age
from 21 to 75 years of age. Three patients had undergone L. radical
nephrectomy, one a R. renal sparing surgery, and two R. radical
nephrectomy.
Time of presentation of pancreatic metastasis varied from 1
to 19 years. In one patient, a distal pancreatic nodule was found
and surgically excised at the time of nephrectomy. Twelve years
later, the patient developed another metastasis to the head of the
pancreas/duodenum.
On Table 2, we present the clinical/pathologic characteristic of
the patients. Three patients had their metastasis discovered dur-
ing routine follow up with CT scan, one patient presented with
abdominal pain, and two patients with GI bleeding.
The site of metastasis was the distal pancreas in four patients
and the duodenal/head of the pancreas in two patients.
Four patients underwent distal pancreatectomy and two
patients pancreatic duodenectomy (Whipple).
The pathology in four patients was a clear cell RCC, one an
unclassified RCC, and one a clear cell carcinoma with rhabdoid
characteristics.
Four patients are alive with periods varying from 1 to 8 years
and two are dead of disease (DOD). Two patients underwent
metastesectomy or cryotherapy for lung metastasis.
Two patients with aggressive tumors have succumbed to their
disease despite several courses of target therapy.
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DISCUSSION
Metastatic tumors of the small bowel are uncommon but cer-
tain tumors may metastasize more frequently than others, such as
melanomas, lung cancer, cervical carcinomas, thyroid carcinomas,
hepatoma, and Merkel cell carcinomas. RCC metastases repre-
sent 7.1% of these lesions and are most frequently located in the
periampullary region or the duodenal bulb (3, 4, 10). Metastatic
lesions to the pancreas are uncommon, accounting for only 5% of
all pancreatic malignancies (7).
The natural history of RCC is unpredictable; the eradication of
the disease is possible after nephrectomy, but there is a possibility
of recurrence years after that. It has the potential to metastasize to
almost any site but the most common sites are lung (75%), lymph
nodes (36%), bone (20%), liver (18%), adrenal glands, kidney,
brain, heart, spleen, intestine, and skin (2). RCC has been cited as
the most common primary tumor leading to solitary pancreatic
metastasis, representing 0.25–3% of all resected pancreatic speci-
mens and the lesions can be multifocal in approximately 30% of
patients and are resectable in approximately 80% of cases (7).
The routes of spreading can be peritoneal dissemination,
hematogenous, lymphatic spread, and direct spread from an intra-
abdominal malignancy (4). A majority of duodenal metastases,
around 70%, occur from the right kidney due to the greater risk
of regional invasion, as the patients we present (3, 6, 15).
The most common clinical presentation of GI metastases of
RCC is GI bleeding, but it may present with abdominal pain,
nausea, weight loss, early satiety, anemia and fatigue, jaundice,
and duodenal obstruction or perforation (1, 16). On the other
hand, pancreatic metastases could be asymptomatic in most
cases and the early signs are often non-specific and subtle. Iso-
lated pancreatic metastases are often found with routine sur-
veillance imaging for primary lesions or as an incidental find-
ing on imaging done for an unrelated indication. Others may
Table 1 | Patient’s demographics.
Patient Sex Age Procedure Time from initial surgery
to metastasis (years)
1 M 75 Renal sparing surgery 19
2 M 58 R nephrectomy 12
3 F 66 R nephrectomy 4
4 F 21 L nephrectomy 2
5 F 52 L nephrectomy 1
6 F 70 L nephrectomy 10
present with abdominal pain (20%), GI bleeding due to duo-
denal infiltration (20%), obstructive jaundice (9%), weight loss
(9%), pancreatitis due to pancreatic duct obstruction (3%), and
pancreatic exocrine/endocrine dysfunction (7, 8, 17–19). In our
experience, one patient presented with GI bleeding and another
was asymptomatic, but his routine follow up allowed us to discover
the recurrence of RCC to the pancreas.
Renal cell carcinoma is the primary tumor that metastasizes to
the pancreas following the long-term disease-free interval, and the
appearance of metastatic disease many years after nephrectomy
is a well-known feature of RCC and is associated with a more
favorable outcome than early recurrences, which tend to have a
more rapid progression of disease (8), which is also seen in two of
our patients (patients 4 and 5), who developed an early metastasis
from the primary resection and died because of that.
The approach to the management of patients with those symp-
toms, and a history of RCC should include a full diagnostic
work-up with radiologic evaluation with a computer tomography
(CT) scan with contrast and/or endoscopic evaluation. In case of
duodenal compromise, the CT scan may show thickening of the
wall or folds in the involved segment and the lesion in the upper
endoscopy can be seen as a submucosal mass with ulceration of the
tip, multiple nodules of different sizes, and raised plaques (3–6).
In case of pancreatic metastasis, the CT scan shows hyper enhanc-
ing lesions that are most pronounced in the early arterial phases
of enhancement, which reflects the hyper vascular nature of these
tumors (19). The most common type RCC metastasis, reported in
50–73% of cases, is that of a solitary, localized, well-defined mass.
A second pattern of multiple pancreatic lesions has been reported
in 5–10% of cases and a third pattern of diffuse metastatic infiltra-
tion causing generalized enlargement of the organ in 15–44% of
cases (20). In our patients, we also appreciate that the most com-
mon pattern of metastasis is a single mass, either in the head of
pancreas or the tail of the pancreas. Although the final diagnosis
is made by biopsy with fine-needle aspiration, we should take into
account the risk of bleeding, which is increased due to the high
vascularity of the tumor. We did not take a biopsy to any patients
before the surgery due to the high risk of bleeding.
Currently, management depends on the general condition of
the patient, the extent and location of the lesion, and the concur-
rent metastases at other sites. In the case of duodenum metastasis
procedures from classic pancreaticoduodenectomy (Whipple pro-
cedure) to interventional embolization have been reported (1–6).
We only use the surgical procedure due to the self-limiting bleeding
in one of our patients.
Table 2 | Clinical pathologic characteristics.
Patient Presenting symptoms Site of metastasis Surgical procedure Pathology Outcome
1 Routine FU Distal pancreas Distal pancreatectomy *CCC Alive
2 GI bleeding Duodenal/head pancreas Whipple *CCC Alive
3 Abdominal pain Duodenal/head pancreas Whipple *CCC Alive
4 Routine FU/CT Distal pancreas Distal pancreatectomy **URCC DOD
5 Retroperitoneal bleeding Distal pancreas/spleen Distal pancreatectomy *CCC DOD
6 Routine FU/CT Distal pancreas Distal pancreatectomy *CCC Alive
*Clear cell carcinoma; **Unclassified RCC.
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Any patient with solitary metastatic RCC to the duodenum
should be a candidate for complete surgical excision if medically
and technically feasible, both for palliation and prognostic reasons,
as it appears to prolong disease-free survival. This kind of surgical
resection has resulted in 5-year survival rates from 35 to 50% and
5-year disease-free survival rate of 5 to 23% (1). But for people with
disseminated malignancy, the average survival is about 4 months
and only 10% of these survive for 1 year, and the treatment is
mainly supportive and palliative (3, 4).
If the patient developed pancreatic metastasis, a standardized
pancreatic resection is used and this is tailored according to the
location of the tumor, including partial pancreaticoduodenec-
tomy, distal pancreatectomy, and total pancreatectomy for the
management of isolated pancreatic metastasis, which can be made
either laparoscopically or through using transumbilical single inci-
sion (8, 21). Five-year survival ranges from 29 to 35% and some
studies reports up to 81%; however, multiple metastatic lesions
carries worse prognosis than solitary ones (7, 22).
Recently, a review of the role of pancreatic metastatic RCC, from
an Italian Center, suggested that pancreatic metastasis was associ-
ated with better prognosis (23). The authors reviewed records of
354 patients with metastatic RCC, 3 with synchronous, and 11 with
metachronous metastasis. Surgical excision was performed in two
patients. Median overall survival was 39 months for patients with
pancreatic metastasis as compared to 23 months for metastatic
disease elsewhere (23).
The advent of target therapy for metastatic RCC has increased
the median tumor-specific survival for those patients (10). The
complete resection of metastasis when found in a single organ,
has considerable impact on survival (11–14).
Because, we cannot closely monitor the patients in this paper,
we can neither quantify the importance of monitoring them,
nor determine for how long should be monitored for metastasis;
further studies are needed to address this issue.
CONCLUSION
Renal cell carcinoma metastasis to duodenum and pancreas is
a rare occurrence; however, with this report, we can intuit that
it is prudent to investigate the presence of any GI symptoms in
these patients to rule out the presence of tumor recurrence and to
consider resection as the procedure of choice whenever possible.
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